On Oct 3, 2016, we issued an updated research report on Glenview, IL-based Mead Johnson Nutrition Company (MJN - Analyst Report) – a global leader in pediatric nutrition, especially for infants and children. The company currently carries a Zacks Rank #3 (Hold).
At present, Mead Johnson markets its products internationally in more than 50 countries and aims to expand its realm even further in the overseas market. This is evident from the substantial progress that the company has made internationally despite the macroeconomic turmoil witnessed in different regions.
In order to capture the untapped potential of less developed regions like Asia, Latin America, the Indian subcontinent and Eastern Europe, the company is working on increasing its sales and operations in these regions. During the last reported second-quarter 2016, it gained strong momentum, particularly in the markets of Mexico, Canada and Malaysia. In fact, in Latin America, where Mead Johnson recorded single-digit growth at CER (excluding Venezuela), Mexico and Colombia were the biggest contributors.
Further, the company has lately adopted a handful of strategic initiatives to effectively improve its operations. Under its WIC (Women, Infants, and Children) program, Mead Johnson recently achieved market leadership in the U.S. infant formula for the first time in several years. Observing the huge potential that the large infant nutrition market holds in the U.S., one of the latest strategies that the company adopted is bidding for new WIC contracts and maintaining the current WIC relationships.
In the second quarter of 2015, Mead Johnson launched Project Fuel for Growth, which is expected to reshape its income statement by increasing operating expense productivity. Evidently, by the end of the first half of 2016, this initiative helped the company cut down $30 million of its expenses from the year-ago period.
On the flip side, unfavorable currency translation continues to be a major dampener for the stock. In the second quarter, foreign exchange headwinds had a 500 basis points (bps), 150 bps and 6 cents impact on the company’s second-quarter sales, gross margin and EPS, respectively. In Asia, foreign exchange headwinds particularly affected sales growth in China and were widespread across the whole of Latin America.
Mead Johnson continues to witness an increase in price-based competition and channel shifts in China that require management to boost additional investment to protect its competitiveness. Intensifying competition and excessive reliance on large customers also pose threats to the stock.
Key Picks in the Sector
Some top-ranked medical stocks are Align Technology Inc. (ALGN - Analyst Report) , Derma Sciences Inc. (DSCI - Snapshot Report) and Antares Pharma Inc. (ATRS - Snapshot Report) . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology has gained 42.4% year to date, much better than the S&P 500’s 6.1% over the same period. Over the past two months, the company has seen two estimates move higher for the current fiscal, compared to no downward movement. Accordingly, earnings estimates for the year have moved up by 0.9% to $2.28 per share over the last 60 days.
Derma Sciences’ current-year earnings growth rate is 94.5%, much higher than the industry’s 7.9%. The stock recorded a gain of 4.9% over the past one year.
Antares Pharma has an impressive earnings growth rate of 42.2% for the next fiscal year, way ahead of the industry growth expectation of 13.5%. Year to date, the stock has performed better than the S&P 500, with a gain of 38.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>